Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02832167
Title An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread (CheckMate 627)
Acronym CheckMate 627
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | DEU


No variant requirements are available.